HMGB1 and colorectal carcinoma: Inhibition of HMGB1 signaling characterized by abnormal expression of specific proteins (IL-6, TNF-α, and HMGB1) relevant to Th cell differentiation was likely the underlying mechanism of CRC treatment by matrine.